首页 | 本学科首页   官方微博 | 高级检索  
   检索      


MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment
Authors:Bernhagen Jürgen  Krohn Regina  Lue Hongqi  Gregory Julia L  Zernecke Alma  Koenen Rory R  Dewor Manfred  Georgiev Ivan  Schober Andreas  Leng Lin  Kooistra Teake  Fingerle-Rowson Günter  Ghezzi Pietro  Kleemann Robert  McColl Shaun R  Bucala Richard  Hickey Michael J  Weber Christian
Institution:Department of Biochemistry and Molecular Cell Biology, Institute of Biochemistry, University Hospital Aachen, Rheinisch-Westf?lische Technische Hochschule (RWTH) Aachen University, D-52074 Aachen, Germany.
Abstract:The cytokine macrophage migration inhibitory factor (MIF) plays a critical role in inflammatory diseases and atherogenesis. We identify the chemokine receptors CXCR2 and CXCR4 as functional receptors for MIF. MIF triggered G(alphai)- and integrin-dependent arrest and chemotaxis of monocytes and T cells, rapid integrin activation and calcium influx through CXCR2 or CXCR4. MIF competed with cognate ligands for CXCR4 and CXCR2 binding, and directly bound to CXCR2. CXCR2 and CD74 formed a receptor complex, and monocyte arrest elicited by MIF in inflamed or atherosclerotic arteries involved both CXCR2 and CD74. In vivo, Mif deficiency impaired monocyte adhesion to the arterial wall in atherosclerosis-prone mice, and MIF-induced leukocyte recruitment required Il8rb (which encodes Cxcr2). Blockade of Mif but not of canonical ligands of Cxcr2 or Cxcr4 in mice with advanced atherosclerosis led to plaque regression and reduced monocyte and T-cell content in plaques. By activating both CXCR2 and CXCR4, MIF displays chemokine-like functions and acts as a major regulator of inflammatory cell recruitment and atherogenesis. Targeting MIF in individuals with manifest atherosclerosis can potentially be used to treat this condition.
Keywords:
本文献已被 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号